Non-Surgical Management of Advanced Squamous Cell Carcinoma by a Novel Agent

Track:
Oculoplastics
What:
Paper Presentation | Présentation d'article
When:
2:02 PM, Friday 10 Jun 2022 (7 minutes)
How:

Authors: Ryan Eidsness, Malshi Kurunatilake, Mussawar Iqbal. University of Saskatchewan.

Author Disclosure Block: R. Eidsness: None. M. Kurunatilake: None. M. Iqbal: None

Abstract Body:

Purpose: Discuss a case of advanced Squamous cell carcinoma (SCC) involving the eyelid, conjunctiva, and orbit that responded to Cemiplimab (Libtayo)

Study Design: Study design: Case Study

Methods: A case study of advanced SCC involving eyelids, conjunctiva and orbit was selected for evaluation. The clinical course of outcomes with follow up of >12 months from treatment conclusion are presented
Results: With the use of cemiplimab the eyelid and orbital component of the SCC completely resolved with the cemiplimab and has remained tumor free for >12 months time. The conjunctival component was aided with the use of topical interferon as well as retinoic acid.

Conclusions: We were able to avoid a large disfiguring exenteration and thus salvage the globe and preserve functional vision in the right eye.
 

Share this